Pharmaceutical Industry, Academia, Regulatory Authorities and End User Collaboration in Successful Drug Discovery and Development

Simple item page
dc.contributor.authorPoduri, Ramarao
dc.date.accessioned2024-01-21T10:38:15Z
dc.date.accessioned2024-08-13T12:05:10Z
dc.date.available2024-01-21T10:38:15Z
dc.date.available2024-08-13T12:05:10Z
dc.date.issued2021-02-18T00:00:00
dc.description.abstractThis chapter reviews the literature on the various factors (time-consuming processes, regulatory requirements, high attrition rate in phase III clinical trials and decrease in RandD productivity) contributed to increase the average cost of drug discovery. A better interaction between the stakeholders, i.e. pharmaceutical industry, academia, regulatory authorities and end users, results in efficacious, safe and affordable drugs to the benefit of the society. � Springer Nature Singapore Pte Ltd. 2021.en_US
dc.identifier.doi10.1007/978-981-15-5534-3_17
dc.identifier.isbn9789811555343
dc.identifier.isbn9789811555336
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/3511
dc.identifier.urlhttp://link.springer.com/10.1007/978-981-15-5534-3_17
dc.language.isoen_USen_US
dc.publisherSpringer Singaporeen_US
dc.subjectAcademiaen_US
dc.subjectPatientsen_US
dc.subjectPharmaceutical Industryen_US
dc.subjectRegulatory Authoritiesen_US
dc.subjectTranslational Researchen_US
dc.titlePharmaceutical Industry, Academia, Regulatory Authorities and End User Collaboration in Successful Drug Discovery and Developmenten_US
dc.title.journalDrug Discovery and Development: From Targets and Molecules to Medicinesen_US
dc.typeBook chapteren_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Pharmaceutical Sciences and Natural Products - Research Publications